Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study)
Tobias Welte, R. Phillip Dellinger, Henning Ebelt, Miguel Ferrer, Steven M. Opal, Mervyn Singer, Jean Louis Vincent, Karl Werdan, Ignacio Martín‐Loeches, Jordi Almirall, Antonio Artigas, Ignacio Ayestarán, Sebastian Nuding, Ricard Ferrer, Gonzalo Sirgo Rodríguez, Manu Shankar‐Hari, Francisco Álvarez-Lerma, Reimer Rießen, Josep-María Sirvent, Stefan Kluge, Kai Zacharowski, Juan Bonastre Mora, Harald Lapp, Gabriele Wöbker, Ute Achtzehn, David Brealey, Axel Kempa, Miguel Sánchez García, Jörg Brederlau, Matthias Kochanek, Henrik Reschreiter, Matt P. Wise, Bernd H. Belohradsky, Iris Bobenhausen, Benjamin Dälken, Patrick Dubovy, Patrick Langohr, Monika Mayer, Jörg Schüttrumpf, Andrea Wartenberg‐Demand, Ulrike Wippermann, Daniele Wolf, Antoní Torres (2018). Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). , 44(4), DOI: https://doi.org/10.1007/s00134-018-5143-7.
